Clinical Trials

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT02298959 2026-04-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04494113 2026-04-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Phase EARLY_PHASE1 Active not recruiting

12 enrolled

Endometrial Serous Adenocarcinoma

NCT04550494 2026-04-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

BreastGastrointestinalGenitourinaryGynecologic

36 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04633239 2026-04-13

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

Phase 1 Recruiting

42 enrolled

BreastGastrointestinalGynecologicHead & NeckSarcoma

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT04704661 2026-04-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Phase 1 Recruiting

51 enrolled

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04840589 2026-04-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Phase 1 Suspended

66 enrolled

Neoplasm Metastasis, Ovarian Neoplasms

NCT05554328 2026-04-13

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05554367 2026-04-13

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

GastrointestinalGynecologic

199 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms

NCT05691504 2026-04-13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

42 enrolled

GynecologicSarcoma

Carcinosarcoma, Fallopian Tube Neoplasms, Endometrial Neoplasms

NCT05950464 2026-04-13

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Phase 1 Recruiting

60 enrolled

Endometrial Neoplasms

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

40 enrolled

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04095364 2026-03-24

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Phase 1/2 Completed

224 enrolled 15 charts

Phase 1/2 Active not recruiting

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

NCT01116648 2026-03-05

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT02345265 2026-03-05

Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

70 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06935344 2026-03-03

PROVE

Recruiting

1,300 enrolled

Genetic Risk Score, Ovarian Neoplasms

NCT07211204 2026-03-03

Comparison Of Cytology And Molecular Screening For Detecting Cervical Reactive Cellular Changes In General Population

Phase NA Withdrawn

Phase 2 Not yet recruiting

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Atypical Squamous Cells of the Cervix

NCT07436793 2026-02-27

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

140 enrolled

Phase 1/2 Active not recruiting

Endometrial Hyperplasia

NCT04432597 2026-02-17

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

39 enrolled

GastrointestinalGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Rectal Neoplasms

NCT05465941 2026-02-09

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

43 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03120624 2026-02-04

VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer

34 enrolled 16 charts

GynecologicOther neoplasm

Endometrial Neoplasms

NCT06815939 2026-01-29

OPTICS

Phase NA Recruiting

10,000 enrolled

Urogenital Diseases, Genital Diseases, Uterine Cervical Diseases, Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Precancerous Conditions, Urogenital Neoplasms, Uterine Diseases, Uterine Neoplasms

NCT04576104 2026-01-21

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

51 enrolled

Endometrial Hyperplasia, Endometrial Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer